Cargando…

The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial

BACKGROUND/OBJECTIVES: The extract from Dendropanax morbifera exhibited diverse therapeutic potentials. We aimed to evaluate the efficacy and safety of D. morbifera leaf extract for improving metabolic parameters in human. SUBJECTS/METHODS: A 12-week, double blind, placebo-controlled and randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Jun, Ji Eun, Hwang, You-Cheol, Ahn, Kyu Jeung, Chung, Ho Yeon, Choung, Se Young, Jeong, In-Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Nutrition Society and the Korean Society of Community Nutrition 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784258/
https://www.ncbi.nlm.nih.gov/pubmed/35116128
http://dx.doi.org/10.4162/nrp.2022.16.1.60
_version_ 1784638695990624256
author Jun, Ji Eun
Hwang, You-Cheol
Ahn, Kyu Jeung
Chung, Ho Yeon
Choung, Se Young
Jeong, In-Kyung
author_facet Jun, Ji Eun
Hwang, You-Cheol
Ahn, Kyu Jeung
Chung, Ho Yeon
Choung, Se Young
Jeong, In-Kyung
author_sort Jun, Ji Eun
collection PubMed
description BACKGROUND/OBJECTIVES: The extract from Dendropanax morbifera exhibited diverse therapeutic potentials. We aimed to evaluate the efficacy and safety of D. morbifera leaf extract for improving metabolic parameters in human. SUBJECTS/METHODS: A 12-week, double blind, placebo-controlled and randomized trial included a total of 74 adults, and they were assigned to the placebo group (n = 38) or 700 mg/day of D. morbifera group (n = 36). The efficacy endpoints were changes in glycemic, lipid, obesity, and blood pressure (BP) parameters, in addition to the prevalence of metabolic syndrome (MetS) and the numbers of MetS components. Safety was assessed by monitoring adverse events (AEs). RESULTS: After 12 weeks of treatment, the hemoglobin A1c (HbA1c) level significantly decreased in the D. morbifera group compared to that of the placebo group (difference: −0.13 ± 0.20% vs. 0.00 ± 0.28%, P = 0.031; % of change: −2.27 ± 3.63% vs. 0.10 ± 5.10%, P = 0.025). The homeostatic model assessment for insulin resistance level also decreased significantly from its baseline in the D. morbifera group. The systolic BP of D. morbifera group decreased significantly than that of placebo group (difference: −3.9 ± 9.8 mmHg vs. 3.3 ± 11.7 mmHg, P = 0.005; % of change: −2.8 ± 7.7% vs. 3.3 ± 10.2%, P = 0.005). However, the lipid parameters and body composition including body weight did not differ between the groups. The prevalence of MetS (36.8% vs. 13.9%, P = 0.022) and the incidence of MetS (10.5% vs. 13.9%, P = 0.027) at 12 weeks was significantly lower in the D. morbifera group than it was in the placebo group. No serious AEs occurred in either group. CONCLUSIONS: Supplementation with D. morbifera extracts over a 12-week period improved metabolic parameters such as HbA1c and BP and reduced the prevalence of MetS. TRIAL REGISTRATION: Clinical Research Information Service Identifier: KCT0004672
format Online
Article
Text
id pubmed-8784258
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Nutrition Society and the Korean Society of Community Nutrition
record_format MEDLINE/PubMed
spelling pubmed-87842582022-02-02 The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial Jun, Ji Eun Hwang, You-Cheol Ahn, Kyu Jeung Chung, Ho Yeon Choung, Se Young Jeong, In-Kyung Nutr Res Pract Original Research BACKGROUND/OBJECTIVES: The extract from Dendropanax morbifera exhibited diverse therapeutic potentials. We aimed to evaluate the efficacy and safety of D. morbifera leaf extract for improving metabolic parameters in human. SUBJECTS/METHODS: A 12-week, double blind, placebo-controlled and randomized trial included a total of 74 adults, and they were assigned to the placebo group (n = 38) or 700 mg/day of D. morbifera group (n = 36). The efficacy endpoints were changes in glycemic, lipid, obesity, and blood pressure (BP) parameters, in addition to the prevalence of metabolic syndrome (MetS) and the numbers of MetS components. Safety was assessed by monitoring adverse events (AEs). RESULTS: After 12 weeks of treatment, the hemoglobin A1c (HbA1c) level significantly decreased in the D. morbifera group compared to that of the placebo group (difference: −0.13 ± 0.20% vs. 0.00 ± 0.28%, P = 0.031; % of change: −2.27 ± 3.63% vs. 0.10 ± 5.10%, P = 0.025). The homeostatic model assessment for insulin resistance level also decreased significantly from its baseline in the D. morbifera group. The systolic BP of D. morbifera group decreased significantly than that of placebo group (difference: −3.9 ± 9.8 mmHg vs. 3.3 ± 11.7 mmHg, P = 0.005; % of change: −2.8 ± 7.7% vs. 3.3 ± 10.2%, P = 0.005). However, the lipid parameters and body composition including body weight did not differ between the groups. The prevalence of MetS (36.8% vs. 13.9%, P = 0.022) and the incidence of MetS (10.5% vs. 13.9%, P = 0.027) at 12 weeks was significantly lower in the D. morbifera group than it was in the placebo group. No serious AEs occurred in either group. CONCLUSIONS: Supplementation with D. morbifera extracts over a 12-week period improved metabolic parameters such as HbA1c and BP and reduced the prevalence of MetS. TRIAL REGISTRATION: Clinical Research Information Service Identifier: KCT0004672 The Korean Nutrition Society and the Korean Society of Community Nutrition 2022-02 2021-06-29 /pmc/articles/PMC8784258/ /pubmed/35116128 http://dx.doi.org/10.4162/nrp.2022.16.1.60 Text en ©2022 The Korean Nutrition Society and the Korean Society of Community Nutrition https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Jun, Ji Eun
Hwang, You-Cheol
Ahn, Kyu Jeung
Chung, Ho Yeon
Choung, Se Young
Jeong, In-Kyung
The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial
title The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial
title_full The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial
title_fullStr The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial
title_full_unstemmed The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial
title_short The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial
title_sort efficacy and safety of dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784258/
https://www.ncbi.nlm.nih.gov/pubmed/35116128
http://dx.doi.org/10.4162/nrp.2022.16.1.60
work_keys_str_mv AT junjieun theefficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial
AT hwangyoucheol theefficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial
AT ahnkyujeung theefficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial
AT chunghoyeon theefficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial
AT choungseyoung theefficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial
AT jeonginkyung theefficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial
AT junjieun efficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial
AT hwangyoucheol efficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial
AT ahnkyujeung efficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial
AT chunghoyeon efficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial
AT choungseyoung efficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial
AT jeonginkyung efficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial